{"id":809696,"date":"2025-02-06T07:03:45","date_gmt":"2025-02-06T12:03:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/"},"modified":"2025-02-06T07:03:45","modified_gmt":"2025-02-06T12:03:45","slug":"astrazenecas-full-year-and-q4-2024-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/","title":{"rendered":"AstraZeneca\u2019s Full Year and Q4 2024 results"},"content":{"rendered":"

<\/p>\n

AstraZeneca\u2019s Full Year and Q4 2024 results<\/b><\/p>\n

Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively<\/i><\/p>\n

CAMBRIDGE, England–(BUSINESS WIRE<\/a>)–
\nAstraZeneca:<\/p>\n

Revenue and EPS summary<\/b><\/p>\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

FY 2024<\/b><\/p>\n<\/td>\n

\n

% Change<\/b><\/p>\n<\/td>\n

\n\n\n

Q4 2024<\/b><\/p>\n<\/td>\n

\n

% Change<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n\n

$m<\/b><\/p>\n<\/td>\n

\n

Actual<\/b><\/p>\n<\/td>\n

\n

CERi<\/sup><\/b><\/p>\n<\/td>\n

\n\n\n

$m<\/b><\/p>\n<\/td>\n

\n

Actual<\/b><\/p>\n<\/td>\n

\n

CER<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\n– Product Sales<\/p>\n<\/td>\n

\n\n

\n50,938<\/p>\n<\/td>\n

\n

\n16<\/p>\n<\/td>\n

\n

\n19<\/p>\n<\/td>\n

\n\n\n

\n13,362<\/p>\n<\/td>\n

\n

\n18<\/p>\n<\/td>\n

\n

\n19<\/p>\n<\/td>\n<\/tr>\n

\n

\n– Alliance Revenue<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2,212<\/p>\n<\/td>\n

\n

\n55<\/p>\n<\/td>\n

\n

\n55<\/p>\n<\/td>\n

\n\n\n

\n714<\/p>\n<\/td>\n

\n

\n68<\/p>\n<\/td>\n

\n

\n69<\/p>\n<\/td>\n<\/tr>\n

\n

\n– Collaboration Revenue<\/p>\n<\/td>\n

\n\n

\n923<\/p>\n<\/td>\n

\n

\n56<\/p>\n<\/td>\n

\n

\n54<\/p>\n<\/td>\n

\n\n\n

\n815<\/p>\n<\/td>\n

\n

\n>2x<\/p>\n<\/td>\n

\n

\n>2x<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Revenue<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n54,073<\/p>\n<\/td>\n

\n

\n18<\/p>\n<\/td>\n

\n

\n21<\/p>\n<\/td>\n

\n\n\n

\n14,891<\/p>\n<\/td>\n

\n

\n24<\/p>\n<\/td>\n

\n

\n25<\/p>\n<\/td>\n<\/tr>\n

\n

\nReported EPS<\/p>\n<\/td>\n

\n\n

\n$4.54<\/p>\n<\/td>\n

\n

\n18<\/p>\n<\/td>\n

\n

\n29<\/p>\n<\/td>\n

\n\n\n

\n$0.97<\/p>\n<\/td>\n

\n

\n56<\/p>\n<\/td>\n

\n

\n71<\/p>\n<\/td>\n<\/tr>\n

\n

\nCoreii<\/sup> EPS<\/p>\n<\/td>\n

\n\n

\n$8.21<\/p>\n<\/td>\n

\n

\n13<\/p>\n<\/td>\n

\n

\n19<\/p>\n<\/td>\n

\n\n\n

\n$2.09<\/p>\n<\/td>\n

\n

\n44<\/p>\n<\/td>\n

\n

\n49<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Financial performance for FY 2024 <\/b>(Growth numbers at constant exchange rates)<\/p>\n

\nTotal Revenue up 21% to $54,073m, driven by a 19% increase in Product Sales, continued growth of partnered medicines (Alliance Revenue) and the achievement of sales-based milestones (Collaboration Revenue)<\/p>\n

\nTotal Revenue growth from Oncology was 24%, CVRM 20%, R&I 25%, V&I 8% and Rare Disease 16%<\/p>\n

\nCore EPS increased 19% to $8.21<\/p>\n

\nSecond interim dividend declared of $2.10 per share, making a total annual dividend declared for FY 2024 of $3.10 per share, an increase of 7%. Dividend to be further increased in FY 2025<\/p>\n

\nGuidance for FY 2025: Total Revenue is expected to increase by a high single-digit percentage and Core EPS is expected to increase by a low double-digit percentage, both at CER<\/p>\n

Pascal Soriot, Chief Executive Officer, AstraZeneca, said:<\/b><\/p>\n

\u201cOur company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also delivered nine positive high value Phase III studies in the year, which coupled with increasing demand for our medicines in all key regions, will help sustain our growth momentum into 2025.<\/i><\/p>\n

This year marks the beginning of an unprecedented, catalyst-rich period for our company, an important step on our Ambition 2030 journey to deliver $80 billion Total Revenue by the end of the decade. In 2025 alone, we anticipate the first Phase III data for seven new medicines, along with several important new indication opportunities for our existing medicines.<\/i><\/p>\n

We are also investing in and making significant progress with transformative technologies that have the potential to drive our growth well beyond 2030, many of which have now entered pivotal trials.\u201d<\/i><\/p>\n

Key milestones achieved since the prior results announcement<\/b><\/p>\n

\nPositive read-outs for Truqap <\/i>in combination with abiraterone and androgen deprivation therapy in PTEN<\/i>-deficient de novo<\/i> metastatic hormone-sensitive prostate cancer (CAPItello-281) and Tagrisso<\/i> with or without chemotherapy in resectable early-stage EGFR<\/i>m NSCLC (NeoADAURA)<\/p>\n

\nUS approvals for Imfinzi <\/i>in limited-stage small cell lung cancer (ADRIATIC), Calquence<\/i> in combination with bendamustine and rituximab in mantle cell lymphoma (ECHO), Datroway <\/i>(datopotamab deruxtecan) in HR+ HER2- metastatic breast cancer (TROPION-Breast01) and Enhertu<\/i> in chemotherapy-na\u00efve HER2-low and -ultralow metastatic breast cancer (DESTINY-Breast06). EU approvals for Tagrisso <\/i>in unresectable EGFR<\/i>m NSCLC (LAURA) and Kavigale<\/i> for prevention of COVID-19 (SUPERNOVA). Japan approvals for Imfinzi <\/i>in endometrial cancer (DUO-E), Lynparza <\/i>plus Imfinzi <\/i>in pMMR endometrial cancer (DUO-E), Calquence<\/i> tablet formulation in chronic \/ small lymphocytic leukaemia, Datroway<\/i> in HR+ HER2- metastatic breast cancer, Fasenra <\/i>in EGPA (MANDARA) and Kavigale<\/i> for prevention of COVID-19. China approvals for Lynparza<\/i> in gBRCAm HER2- early breast cancer (OlympiA), Orpathys <\/i>in locally advanced or metastatic MET Exon 14 NSCLC (NCT04923945)<\/p>\n

Guidance<\/b><\/p>\n

\nThe Company issues its Total Revenue and Core EPS guidance for FY 2025 at CER, based on the average foreign exchange rates through 2024.<\/p>\n\n\n
\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nTotal Revenue is expected to increase by a high single-digit percentage
\n
Core EPS is expected to increase by a low double-digit percentage<\/p>\n\n\n
\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nThe Core Tax rate is expected to be between 18-22%<\/p>\n

\nThe Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.<\/p>\n

Currency impact<\/b><\/p>\n

\nIf foreign exchange rates for February 2025 to December 2025 were to remain at the average rates seen in January 2025, it is anticipated that Total Revenue in FY 2025 would incur a low single-digit percentage adverse impact compared to the performance at CER, and Core EPS would incur a mid-single-digit percentage adverse impact. The Company\u2019s foreign exchange rate sensitivity analysis is provided in Table 17.<\/p>\n

Capital allocation<\/b><\/p>\n

\nIn FY 2025, the Company intends to increase the annual dividend declared to $3.20 per share. The Company also expects to increase capital expenditureiii<\/sup> by approximately 50%, driven by manufacturing expansion projects and investment in IT systems, to support portfolio growth and build capacity for transformative technologies.<\/p>\n

China<\/b><\/p>\n

\nIn relation to the illegal drug importation allegations, in January 2025, AstraZeneca received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $0.9 million. To the best of AstraZeneca\u2019s knowledge, the importation taxes referred to in the Appraisal Opinion relate to Imfinzi<\/i> and Imjudo<\/i>. A fine of between one and five times the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable. AstraZeneca continues to fully cooperate with the Chinese authorities.<\/p>\n

\nIn December 2024 AstraZeneca announced the appointment of Iskra Reic as Executive Vice President, International, which encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand. Iskra succeeds Leon Wang who is on extended leave from the Company while under investigation in China.<\/p>\n

Table 1: Key elements of Total Revenue performance in Q4 2024<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n\n\n

% Change<\/b><\/p>\n<\/td>\n

\n<\/tr>\n
\n

Revenue type<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

$m<\/b><\/p>\n<\/td>\n

\n

Actual %<\/b><\/p>\n<\/td>\n

\n

CER %<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nProduct Sales<\/p>\n<\/td>\n

\n\n

\n13,362<\/p>\n<\/td>\n

\n

\n18<\/p>\n<\/td>\n

\n

\n19<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nAlliance Revenue<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n714<\/p>\n<\/td>\n

\n

\n68<\/p>\n<\/td>\n

\n

\n69<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$392m Enhertu<\/i> (Q4 2023: $281m)<\/p>\n

\n$133m Tezspire<\/i> (Q4 2023: $80m)<\/p>\n

\n$161m Beyfortus <\/i>(Q4 2023: $41m)<\/p>\n<\/td>\n<\/tr>\n

\n

\nCollaboration Revenue<\/p>\n<\/td>\n

\n\n

\n815<\/p>\n<\/td>\n

\n

\n>2x<\/p>\n<\/td>\n

\n

\n>2x<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$600m Lynparza <\/i>(Q4 2023: $245m)<\/p>\n

\n$111m Beyfortus <\/i>(Q4 2023: $27m)<\/p>\n

\n$100m Koselugo <\/i>(Q4 2023: nil)<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Revenue<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n14,891<\/p>\n<\/td>\n

\n

\n24<\/p>\n<\/td>\n

\n

\n25<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Therapy areas<\/b><\/p>\n<\/td>\n

\n\n

$m<\/b><\/p>\n<\/td>\n

\n

Actual %<\/b><\/p>\n<\/td>\n

\n

CER %<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nOncology<\/p>\n<\/td>\n

\n\n

\n6,344<\/p>\n<\/td>\n

\n

\n27<\/p>\n<\/td>\n

\n

\n29<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

Tagrisso<\/i> up 20% (21% at CER), Calquence<\/i> up 20%, Enhertu <\/i>up 48% (54% at CER)<\/p>\n<\/td>\n<\/tr>\n

\n

\nCVRM<\/p>\n<\/td>\n

\n\n

\n3,138<\/p>\n<\/td>\n

\n

\n16<\/p>\n<\/td>\n

\n

\n17<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

Farxiga <\/i>up 21% (22% at CER),<\/i>Lokelma <\/i>up35%<\/p>\n<\/td>\n<\/tr>\n

\n

\nR&I<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2,127<\/p>\n<\/td>\n

\n

\n27<\/p>\n<\/td>\n

\n

\n28<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

Breztri<\/i> up 29%. Saphnelo <\/i>up 65%, Tezspire <\/i>up 86% (85% at CER), Symbicort <\/i>up 31% (33% CER)<\/p>\n<\/td>\n<\/tr>\n

\n

\nV&I<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n651<\/p>\n<\/td>\n

\n

\n58<\/p>\n<\/td>\n

\n

\n55<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

Beyfortus<\/i> Total Revenue up >3x<\/p>\n<\/td>\n<\/tr>\n

\n

\nRare Disease<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2,377<\/p>\n<\/td>\n

\n

\n21<\/p>\n<\/td>\n

\n

\n22<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

Ultomiris<\/i> up 32% (33% at CER), partially offset by decline in Soliris<\/i> of 24% (22% at CER), Strensiq<\/i> up 38% (37% at CER) and Koselugo<\/i> up >3x<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther Medicines<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n254<\/p>\n<\/td>\n

\n

\n(7)<\/p>\n<\/td>\n

\n

\n(6)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Revenue<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n14,891<\/p>\n<\/td>\n

\n

\n24<\/p>\n<\/td>\n

\n

\n25<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Regions<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

$m<\/b><\/p>\n<\/td>\n

\n

Actual %<\/b><\/p>\n<\/td>\n

\n

CER %<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nUS<\/p>\n<\/td>\n

\n\n

\n6,532<\/p>\n<\/td>\n

\n

\n28<\/p>\n<\/td>\n

\n

\n28<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nProduct Sales up 25%<\/p>\n<\/td>\n<\/tr>\n

\n

\nEmerging Markets<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n3,134<\/p>\n<\/td>\n

\n

\n13<\/p>\n<\/td>\n

\n

\n19<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

– China<\/i><\/p>\n<\/td>\n

\n\n

\n1,364<\/p>\n<\/td>\n

\n

\n(1)<\/p>\n<\/td>\n

\n

\n(3)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nDecline primarily due to low rates of seasonal respiratory viral infections, and impact from year-end hospital budget dynamics<\/p>\n<\/td>\n<\/tr>\n

\n

– Ex-China Emerging Markets<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n1,770<\/p>\n<\/td>\n

\n

\n26<\/p>\n<\/td>\n

\n

\n42<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nEurope<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n3,948<\/p>\n<\/td>\n

\n

\n37<\/p>\n<\/td>\n

\n

\n35<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nProduct Sales up 20% (18% at CER)<\/p>\n<\/td>\n<\/tr>\n

\n

\nEstablished RoW<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n1,277<\/p>\n<\/td>\n

\n

\n1<\/p>\n<\/td>\n

\n

\n2<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Revenue<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n14,891<\/p>\n<\/td>\n

\n

\n24<\/p>\n<\/td>\n

\n

\n25<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Key alliance medicines<\/b><\/p>\n

\nCombined sales of Enhertu<\/i>, recorded by Daiichi Sankyo Company Limited (Daiichi Sankyo) and AstraZeneca, amounted to $3,754m in FY 2024 (FY 2023: $2,566m)<\/p>\n

\nCombined sales of Tezspire<\/i>, recorded by Amgen and AstraZeneca, amounted to $1,219m in FY 2024 (FY 2023: $653m)<\/p>\n

Table 2: Key elements of financial performance in Q4 2024<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\n

Metric<\/b><\/p>\n<\/td>\n

\n

Reported<\/b><\/p>\n<\/td>\n

\n

Reported
\n
change<\/b><\/p>\n<\/td>\n

\n

Core<\/b><\/p>\n<\/td>\n

\n

Core
\n
change<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

Commentsiv<\/sup><\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Revenue<\/p>\n<\/td>\n

\n

\n$14,891m<\/p>\n<\/td>\n

\n

\n24% Actual
\n
25% CER<\/p>\n<\/td>\n

\n

\n$14,891m<\/p>\n<\/td>\n

\n

\n24% Actual
\n
25% CER<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nSee Table 1 and the Total Revenue section of this document for further details<\/p>\n<\/td>\n<\/tr>\n

\n

\nProduct Sales Gross Margin<\/p>\n<\/td>\n

\n

\n80%<\/p>\n<\/td>\n

\n

\nStable Actual
\n
+1pp CER<\/p>\n<\/td>\n

\n

\n79%<\/p>\n<\/td>\n

\n

\n-1pp Actual
\n
Stable CER<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nVariations in Product Sales Gross Margin can be expected between periods, due to product seasonality, foreign exchange fluctuations and other effects<\/p>\n<\/td>\n<\/tr>\n

\n

\nR&D<\/p>\n

\nexpense<\/p>\n<\/td>\n

\n

\n$4,677m<\/p>\n<\/td>\n

\n

\n52% Actual
\n
52% CER<\/p>\n<\/td>\n

\n

\n$3,573m<\/p>\n<\/td>\n

\n

\n23% Actual
\n
22% CER<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nIncreased investment in the pipeline<\/p>\n

\nCore R&D-to-Total Revenue ratio of 24%
\n
(Q4 2023: 24%)
\n
Reported R&D includes $753m impairment recorded against the vemircopan (ALXN2050) intangible asset<\/p>\n<\/td>\n<\/tr>\n

\n

\nSG&A expense<\/p>\n<\/td>\n

\n

\n$5,410m<\/p>\n<\/td>\n

\n

\n1% Actual
\n
1% CER<\/p>\n<\/td>\n

\n

\n$4,275m<\/p>\n<\/td>\n

\n

\n6% Actual
\n
7% CER<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nMarket development for recent launches and pre-launch activities
\n
Core SG&A-to-Total Revenue ratio of 29%
\n
(Q4 2023: 34%)<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther operating income and expensev<\/sup><\/p>\n<\/td>\n

\n

\n$100m<\/p>\n<\/td>\n

\n

\n-7% Actual
\n
-6% CER<\/p>\n<\/td>\n

\n

\n$101m<\/p>\n<\/td>\n

\n

\n-7% Actual
\n
-6% CER<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating Margin<\/p>\n<\/td>\n

\n

\n14%<\/p>\n<\/td>\n

\n

\n+3pp Actual
\n
+4pp CER<\/p>\n<\/td>\n

\n

\n28%<\/p>\n<\/td>\n

\n

\n+5pp Actual
\n
+6pp CER<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nSee commentary above on Gross Margin, R&D, SG&A and Other operating income and expense<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet finance expense<\/p>\n<\/td>\n

\n

\n$365m<\/p>\n<\/td>\n

\n

\n9% Actual
\n
8% CER<\/p>\n<\/td>\n

\n

\n$310m<\/p>\n<\/td>\n

\n

\n20% Actual
\n
20% CER<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nRecent debt issued at higher interest rates
\n
Decrease in interest income
\n
Higher level of Net debt<\/p>\n<\/td>\n<\/tr>\n

\n

\nTax rate<\/p>\n<\/td>\n

\n

\n10%<\/p>\n<\/td>\n

\n

\n+17pp Actual
\n
+15pp CER<\/p>\n<\/td>\n

\n

\n16%<\/p>\n<\/td>\n

\n

\n+7pp Actual
\n
+7pp CER<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nVariations in the tax rate can be expected between periods<\/p>\n<\/td>\n<\/tr>\n

\n

\nEPS<\/p>\n<\/td>\n

\n

\n$0.97<\/p>\n<\/td>\n

\n

\n56% Actual
\n
71% CER<\/p>\n<\/td>\n

\n

\n$2.09<\/p>\n<\/td>\n

\n

\n44% Actual
\n
49% CER<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nFurther details of differences between Reported and Core are shown in Table 12<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Table 3: Pipeline highlights since prior results announcement<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Event<\/b><\/p>\n<\/td>\n

\n

Medicine<\/b><\/p>\n<\/td>\n

\n

Indication \/ Trial<\/b><\/p>\n<\/td>\n

\n

Event<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nRegulatory approvals and other regulatory actions<\/p>\n<\/td>\n

\n

Tagrisso<\/i><\/p>\n<\/td>\n

\n

EGFR<\/i>m NSCLC (Stage III<\/p>\n

\nunresectable) (LAURA)<\/p>\n<\/td>\n

\n

\nRegulatory approval (EU, CN)<\/p>\n<\/td>\n<\/tr>\n

\n

Imfinzi<\/i><\/p>\n<\/td>\n

\n

\nLimited-stage SCLC (ADRIATIC)<\/p>\n<\/td>\n

\n

\nRegulatory approval (EU)<\/p>\n<\/td>\n<\/tr>\n

\n

Imfinzi<\/i><\/p>\n<\/td>\n

\n

\nAdvanced endometrial cancer<\/p>\n<\/td>\n

\n

\nRegulatory approval (JP)<\/p>\n<\/td>\n<\/tr>\n

\n

Calquence<\/i><\/p>\n<\/td>\n

\n

\nTablets for chronic lymphocytic leukaemia<\/p>\n<\/td>\n

\n

\nRegulatory approval (JP)<\/p>\n<\/td>\n<\/tr>\n

\n

Calquence<\/i><\/p>\n<\/td>\n

\n

\nMantle cell lymphoma (1st-line) (ECHO)<\/p>\n<\/td>\n

\n

\nRegulatory approval (US)<\/p>\n<\/td>\n<\/tr>\n

\n

Lynparza + Imfinzi<\/i><\/p>\n<\/td>\n

\n

\nAdvanced endometrial cancer with mismatch repair proficiency<\/p>\n

\n(DUO-E)<\/p>\n<\/td>\n

\n

\nRegulatory approval (JP)<\/p>\n<\/td>\n<\/tr>\n

\n

Lynparza<\/i><\/p>\n<\/td>\n

\n

\ngBRCAm HER2- eBC (OlympiA)<\/p>\n<\/td>\n

\n

\nRegulatory approval (CN)<\/p>\n<\/td>\n<\/tr>\n

\n

Enhertu<\/i><\/p>\n<\/td>\n

\n

\nHR+ HER2-low and -ultralow mBC<\/p>\n

\n(DESTINY-Breast06)<\/p>\n<\/td>\n

\n

\nRegulatory approval (US)<\/p>\n<\/td>\n<\/tr>\n

\n

Datroway<\/i><\/p>\n<\/td>\n

\n

\nHR+ HER2- mBC (TROPION-Breast01)<\/p>\n<\/td>\n

\n

\nRegulatory approval (JP, US)<\/p>\n<\/td>\n<\/tr>\n

\n

Orpathys<\/i><\/p>\n<\/td>\n

\n

\nMET exon 14 skipping altered NSCLC (NCT04923945)<\/p>\n<\/td>\n

\n

\nRegulatory approval (CN)<\/p>\n<\/td>\n<\/tr>\n

\n

Fasenra<\/i><\/p>\n<\/td>\n

\n

\nEGPA (MANDARA)<\/p>\n<\/td>\n

\n

\nRegulatory approval (JP)<\/p>\n<\/td>\n<\/tr>\n

\n

Kavigale<\/i><\/p>\n<\/td>\n

\n

\nPrevention of COVID-19 (SUPERNOVA)<\/p>\n<\/td>\n

\n

\nRegulatory approval (EU, JP)<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nRegulatory submissions or acceptances*<\/p>\n<\/td>\n

\n

Imfinzi<\/i><\/p>\n<\/td>\n

\n

\nMuscle-invasive bladder<\/p>\n

\ncancer (NIAGARA)<\/p>\n<\/td>\n

\n

\nRegulatory submission (US, JP)<\/p>\n<\/td>\n<\/tr>\n

\n

Imfinzi + Imjudo<\/i><\/p>\n<\/td>\n

\n

\nNSCLC (1st-line) (POSEIDON)<\/p>\n<\/td>\n

\n

\nRegulatory submission (CN)<\/p>\n<\/td>\n<\/tr>\n

\n

Calquence<\/i><\/p>\n<\/td>\n

\n

\nChronic lymphocytic leukaemia (1st-line) (AMPLIFY)<\/p>\n<\/td>\n

\n

\nRegulatory submission (EU)<\/p>\n<\/td>\n<\/tr>\n

\n

Datroway<\/i><\/p>\n<\/td>\n

\n

EGFR<\/i>m NSCLC (later line) (TROPION-Lung05)<\/p>\n<\/td>\n

\n

\nRegulatory submission (US)<\/p>\n<\/td>\n<\/tr>\n

\n

Tezspire<\/i><\/p>\n<\/td>\n

\n

\nSevere uncontrolled asthma (NAVIGATOR\/<\/p>\n

\nDIRECTION)<\/p>\n<\/td>\n

\n

\nRegulatory submission (CN)<\/p>\n<\/td>\n<\/tr>\n

\n

Koselugo<\/i><\/p>\n<\/td>\n

\n

\nNeurofibromatosis type 1 adult (KOMET)<\/p>\n<\/td>\n

\n

\nRegulatory submission (EU, JP)<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nPhase III \/ registrational data readouts and other developments<\/p>\n<\/td>\n

\n

Tagrisso<\/i><\/p>\n<\/td>\n

\n

\nResectable early-stage EGFR<\/i>m NSCLC(NeoADAURA)<\/p>\n<\/td>\n

\n

\nPrimary endpoint met<\/p>\n<\/td>\n<\/tr>\n

\n

Truqap<\/i><\/p>\n<\/td>\n

\n

PTEN<\/i>-deficient de novo metastatic hormone-sensitive prostate cancer (CAPItello-281)<\/p>\n<\/td>\n

\n

\nPrimary endpoint met<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n\n\n\u00a0<\/td>\n<\/tr>\n
\n

*US, EU and China regulatory submission denotes filing acceptance<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Other pipeline updates<\/b><\/p>\n

\nIn January 2025, the vemircopan (ALXN2050) Phase II development programme was terminated. The decision was based on safety and efficacy data from Phase II trials.<\/p>\n

Upcoming pipeline catalysts<\/b><\/p>\n

\nFor recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, available on www.astrazeneca.com\/investor-relations.html<\/a>.<\/p>\n

Sustainability highlights<\/b><\/p>\n

\nThe Company convened an event on health equity for investors and analysts in November that detailed AstraZeneca\u2019s health equity strategy, which is embedded from the Company\u2019s science through to healthcare delivery and community engagement.<\/p>\n

\nAt the end of 2024, the Company\u2019s cumulative reduction in Scope 1 and 2 greenhouse gas (GHG) emissions was 77.5% from the 2015 baseline.<\/p>\n

Conference call<\/b><\/p>\n

\nA conference call and webcast for investors and analysts will begin today, 6 February 2025, at 11:00 UK time. Details can be accessed via astrazeneca.com<\/a>.<\/p>\n

Reporting calendar<\/b><\/p>\n

\nThe Company intends to publish its Q1 2025 results on 29 April 2025.<\/p>\n

\nTo read AstraZeneca’s Full Year and Q4 2024 Financial Results press release in full, click here<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250205200649\/en\/<\/a><\/span><\/p>\n

\nGlobal Media Relations team
\n
global-mediateam@astrazeneca.com
\n<\/a>
+44 (0)1223 344 800<\/p>\n

KEYWORDS:<\/b> United Kingdom Europe<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Infectious Diseases Pharmaceutical Cardiology Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

AstraZeneca\u2019s Full Year and Q4 2024 results Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively CAMBRIDGE, England–(BUSINESS WIRE)– AstraZeneca: Revenue and EPS summary \u00a0 \u00a0 FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER – Product Sales 50,938 16 19 13,362 18 19 – Alliance Revenue \u00a0 2,212 55 55 714 68 69 – Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue \u00a0 54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29 $0.97 56 71 Coreii EPS $8.21 13 19 $2.09 44 49 Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m, driven by a … <\/p>\n

Continue reading “AstraZeneca\u2019s Full Year and Q4 2024 results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-809696","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAstraZeneca\u2019s Full Year and Q4 2024 results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca\u2019s Full Year and Q4 2024 results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca\u2019s Full Year and Q4 2024 results Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively CAMBRIDGE, England–(BUSINESS WIRE)– AstraZeneca: Revenue and EPS summary \u00a0 \u00a0 FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER – Product Sales 50,938 16 19 13,362 18 19 – Alliance Revenue \u00a0 2,212 55 55 714 68 69 – Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue \u00a0 54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29 $0.97 56 71 Coreii EPS $8.21 13 19 $2.09 44 49 Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m, driven by a … Continue reading "AstraZeneca\u2019s Full Year and Q4 2024 results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T12:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AstraZeneca\u2019s Full Year and Q4 2024 results\",\"datePublished\":\"2025-02-06T12:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/\"},\"wordCount\":1720,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/\",\"name\":\"AstraZeneca\u2019s Full Year and Q4 2024 results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-02-06T12:03:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/astrazenecas-full-year-and-q4-2024-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca\u2019s Full Year and Q4 2024 results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca\u2019s Full Year and Q4 2024 results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca\u2019s Full Year and Q4 2024 results - Market Newsdesk","og_description":"AstraZeneca\u2019s Full Year and Q4 2024 results Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively CAMBRIDGE, England–(BUSINESS WIRE)– AstraZeneca: Revenue and EPS summary \u00a0 \u00a0 FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER – Product Sales 50,938 16 19 13,362 18 19 – Alliance Revenue \u00a0 2,212 55 55 714 68 69 – Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue \u00a0 54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29 $0.97 56 71 Coreii EPS $8.21 13 19 $2.09 44 49 Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m, driven by a … Continue reading \"AstraZeneca\u2019s Full Year and Q4 2024 results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-06T12:03:45+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AstraZeneca\u2019s Full Year and Q4 2024 results","datePublished":"2025-02-06T12:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/"},"wordCount":1720,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/","name":"AstraZeneca\u2019s Full Year and Q4 2024 results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-02-06T12:03:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250205200649r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/astrazenecas-full-year-and-q4-2024-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca\u2019s Full Year and Q4 2024 results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=809696"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/809696\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=809696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=809696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=809696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}